Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Gains from Investment Securities data on record, last reported at -$8000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$8000.0; the TTM value through Dec 2025 reached -$758000.0, changed 0.26%, while the annual FY2025 figure was -$50000.0, 100.37% down from the prior year.
  • Gains from Investment Securities reached -$8000.0 in Q4 2025 per CRNX's latest filing, down from $15.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.0 million in Q2 2025 and bottomed at -$5.6 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $3.5 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: tumbled 62322.22% in 2022, then skyrocketed 235737.42% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $9000.0 in 2021, then crashed by 62322.22% to -$5.6 million in 2022, then skyrocketed by 87.36% to -$708000.0 in 2023, then surged by 806.21% to $5.0 million in 2024, then tumbled by 100.16% to -$8000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$8000.0 in Q4 2025, $15.0 million in Q2 2025, and $2.1 million in Q1 2025.